Phase 2 expansion into first line maintenance therapy follows positive interim results reported in 2018 in combination with Bristol-Myers' Opdivo (Nivolumab)
DURHAM, NC / ACCESSWIRE / January 14, 2019 / Heat Biologics, Inc. (NASDAQ: HTBX), a biopharmaceutical company developing therapies designed to activate a patient's immune system against cancer, today announced that it has dosed its first patient in its Phase 2 clinical trial investigating HS-110 in combination with Merck's anti-PD1 checkpoint inhibitor, KEYTRUDA (pembrolizumab), in patients with advanced non-small cell lung cancer (NSCLC). This expansion of the Company's Phase 2 trial into... More